The backtest results for VALN show mixed performance following earnings beats, with a 50% win rate at both 3 and 10 days, but a 0% win rate at 30 days. Short-term returns are modestly positive, peaking at 3.69% over 10 days, while the 30-day return turns negative at -7.51%. This suggests initial optimism fades over a longer horizon. The maximum return observed was 12.48% on day 54, indicating potential for delayed gains. Investors should consider short-term opportunities post-earnings beat but remain cautious about longer-term holdings.

backtest_data

The backtest results for VALN following earnings misses show a mixed performance with a 62.5% win rate at 3 and 30 days but only 50% at 10 days. Returns are slightly negative over 30 days (-0.86%) despite a modest positive return at 10 days (0.13%). This suggests short-term volatility with limited sustained gains. The maximum return observed was 1.5% around day 6, indicating some recovery potential. Investors should be cautious as earnings misses do not consistently lead to negative outcomes but may imply modest downside risk over the medium term.

The backtest results show that the Biotechnology Industry experienced a negative impact following earnings beats, with a maximum return of only 0.19% on the event day. This suggests that despite positive earnings surprises, the sector does not gain significant immediate value and may even face short-term headwinds. The analysis indicates that earnings beats in this industry do not translate into strong positive price movements, highlighting a cautious market reaction. Investors should consider this muted response when evaluating biotech stocks post-earnings beat and may need to look beyond immediate returns for investment decisions.

The backtest results show that earnings misses in the Biotechnology Industry have no significant impact on stock returns, with a maximum return of only 0.01% observed three days after the event. This indicates that the industry’s stock prices are largely unaffected by earnings misses over the tested period.

The lack of meaningful price movement suggests that investors may have already priced in such earnings outcomes or that other factors dominate stock performance in this sector.

For investors, this implies limited trading opportunities based solely on earnings misses within the Biotechnology Industry.

Backtest VALN Release Earning Report

Find all upcoming company earnings reports scheduled for mar 01 2026. Get details on which companies are reporting and their expected results.

Calendar